Linden Thomas Advisory Services’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Linden Thomas Advisory Services’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Sell	54,803 -66,974	-55%	-$3.47M	0.28%	90
2026 Q1	$5.86M	Buy	121,777 +7,315	+6%	+$324K	0.57%	22
2025 Q4	$4.72M	Sell	114,462 -1,578	-1%	-$63.3K	0.48%	48
2025 Q3	$4.51M	Sell	116,040 -75	-0.1%	-$2.44K	0.46%	51
2025 Q2	$3.21M	Sell	116,115 -1,166	-1%	-$29.7K	0.35%	74
2025 Q1	$2.6M	Sell	117,281 -323	-0.3%	-$6.65K	0.34%	80
2024 Q4	$2.33M	Sell	117,604 -106	-0.1%	-$2.42K	0.29%	99
2024 Q3	$2.94M	Sell	117,710 -592	-0.5%	-$14.4K	0.4%	55
2024 Q2	$2.21M	Buy	118,302 +1,921	+2%	+$36K	0.34%	72
2024 Q1	$2.3M	Buy	116,381 +1,831	+2%	+$35.8K	0.37%	61
2023 Q4	$2.01M	Sell	114,550 -1,341	-1%	-$22K	0.38%	66
2023 Q3	$2.01M	Buy	115,891 +57,942	+100%	+$976K	0.45%	45
2023 Q2	$816K	Buy	+57,949	New	+$776K	0.18%	230

Other funds holding KNSA

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Linden Thomas Advisory Services's KNSA Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Kiniksa Pharmaceuticals (KNSA) stake by 55% in Q2 2026, selling an estimated $3.47M and leaving 54,803 shares worth $3.5M. The position accounts for 0.28% of the portfolio, ranked #90.

Linden Thomas Advisory Services first reported a position in KNSA in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.86M in Q1 2026. 16 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Linden Thomas Advisory Services held 54,803 shares of Kiniksa Pharmaceuticals worth $3.5M as of Q2 2026.
Linden Thomas Advisory Services sold 66,974 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.47M.
Kiniksa Pharmaceuticals made up 0.28% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #90 holding.
Linden Thomas Advisory Services first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Linden Thomas Advisory Services's Kiniksa Pharmaceuticals position peaked at $5.86M in Q1 2026.
16 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.